With Buy Not an Option in China s Economy, Chipscreen Goes for Build | GenomeWeb

By China’s standards, Chipscreen Biosciences is a biotech success story. The two-year old drug discovery firm, based in Shenzhen, Guangdong, has raised over $6 million in funding, which is “quite unusual in China” according to Leming Shi, co-founder and director of informatics. But despite its relatively deep pockets, Chipscreen found that commercial informatics systems were still out of its price range.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.